Hacked by islam_Bey imhatimi.org

With reference to the earlier announcement dated June 17, 2008 about “in principle” decision taken by the Board of Directors of Cadila Healthcare Ltd (Cadila) at its meeting held on June 17, 2008 to consolidate / restructure the Consumer Products Division (CPD) of Cadila with its subsidiary Company, namely “Carnation Nutra-Analogue Foods Ltd (Carnation), subject to the promoters of Cadila agreeing to consider restructuring of their shareholding in Cadila and to take appropriate steps so as to enable that Carnation continues to remain a listed subsidiary of Cadila, after such restructure and announcement dated June 19, 2008 issued by an Independent Director, authorised by the Board of Directors, communicating the decision of the promoters to be part of the Scheme for transfer of Cadila’s Consumer Products Division (CPD) into Carnation which may be finalised and approved by the Board of Cadila and to facilitate the above agreeing to transfer their shareholding in Cadila to Zydus Hospitals and Medical Research Pvt Ltd, which is also owned by Zydus Family Trust, Cadila Healthcare Ltd has informed BSE that a meeting of the Board of the Directors of the Company will be held on July 04, 2008 to approve the “Composite Scheme of Arrangement between Cadila, Carnation and Zydus Hospitals and Medical Research Pvt Ltd” to effect restructuring of the Consumer Products Division of Cadila and Carnation and also to realign the holding structure of the Company into Carnation based on the recommendations of consultants and to approve share swap ratios, under the Scheme, and considering the reports of the valuers.

Cadila Healthcare Ltd has informed BSE that the members of the Company, by way of postal ballot, have passed the Ordinary Resolution relating to mortgage and / or create charge on all or any one or more of the movable / immovable properties or such other assets of the Company in favour of lenders of the Company, with overwhelming majority.

Cadila Healthcare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 17, 2008, had taken in-principle decision to transfer Cadila’s Consumer Products Division (”CPD”) into Carnation Nutra Analogue Foods Ltd (”Carnation”), 61.56% subsidiary of the Cadila.

While the Board of Cadila has in-principle agreed to the above restructuring, it had requested the promoters of Cadila to consider restructuring of their shareholding in Cadila and take appropriate steps so as to ensure that Carnation continues to remain listed subsidiary of Cadila.

Considering the request of the Board, the overall interest of Cadila and its shareholders at large and to facilitate Cadila retain its control over Carnation and ensure that Carnation remains a subsidiary of Cadila after restructuring of the consumer health business as aforesaid, the Promoters of Cadila have agreed

- to be part of the scheme for transfer of Cadila’s CPD Into Carnation which may be finalized and approved by the Board of Cadila

and

- to facilitate the above, transfer 90,000,000 shares out of the existing holding of 90,442,850 equity shares of the promoters in Cadila to Zydus Hospitals and Medical Research Pvt Ltd, which is also owned by Zydus Family Trust, subject to the applicable regulations and compliances of the SEBI (SAST) Regulations, 1997 and any other relevant provisions of the law.

Cadila Healthcare Ltd has informed BSE that the Board of Directors of the Company at its meeting held on June 17, 2008, inter alia, has transacted the following:

- Decided “in principle” to consolidate / restructure the Consumer Products Division with its subsidiary Company, namely Carnation Nutra Analogue-Foods Ltd (Carnation}, (which is also into similar business activity), subject to the promoters of the Company agreeing to the request of the Board of the Company to consider restructuring of their shareholding in the Company, under a structure wherein Carnation continues to remain a listed subsidiary of the Company.

- Authorised an independent director of the Company to consider and accept the decision
of the promoters, if the promoters agree to restructure their shareholding in line with the aforesaid objective and thereafter appoint advisors / consultants / Chartered Accountants to finalise structure of scheme including valuation to determine the share exchange ratio in relation to the proposed restructuring.

- Final decision on the scheme and share swap ratio will be taken at a subsequent board meeting, if the promoters agree to the restructuring of their shareholding in the Company aforesaid.

Cadila Healthcare Ltd has informed BSE that the Company through its wholly owned subsidiary - Zydus Healthcare SA PTY. Ltd. is acquiring majority state of 70% in Simayla
Pharmaceuticals of South Africa. As per the agreement reached between the two Companies, the remaining stake will be held by the promoter of the Company.

In this regard the Company has issued the following Press Release dated June 09, 2008 titled “Zydus acquires majority stake in Simayla Pharmaceuticals of South Africa”

Cadila Healthcare Ltd has informed BSE regarding Notice of Postal Ballot despatched to the members of the Company for according their consent under Section 293(1)(a) of the Companies Act, 1956 empowering the Board of Directors to mortgage and/or charge properties of the Company for securing financial assistance availed / to be availed from any Bank / Financial institutions / other entities, the same may please receive in order.

Cadila Healthcare Ltd has informed BSE regarding a Press Release dated May 15, 2008 titled “New Product Approvals for Zydus Cadila from USFDA”

“Zydus Cadila has received four product approvals from the USFDA. The group has received approvals to market Pravastatin Sodium Tablets USP 10, 20, 40 and 80 mg and tentative approvals for Escitalopram Oxalate Tablets, 5, 10 and 20 mg, Losartan Potassium and Hydrochlorthiazide Tablets 50 mg / 12.5 mg and 100 mg / 25 mg and Anastrazole Tablets 1 mg.

The US market of Pravastatin Sodium Tablets, a lipid lowering agent which falls in the cardiovascular segment, was estimated at USD 1.9 billion in 2007, while the branded sales of Escitalopram Oxalate Tablets, an anti-depressant, was estimated at USD 3 billion. Losartan Potassium and Hydrochlorthiazide Tablets, an anti-hypertensive, was estimated at USD 785 million and that of Anastrazole Tablets, a hormone therapy to treat breast cancer, was estimated at USD 813 million in 2007 as per NDC.”

Cadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on April 29, 2008, inter alia, to consider the audited Annual Accounts of the Company for the year ended March 31, 2008 and the Board will also consider the recommendation of dividend on Equity Shares for the year 2007-08.

Cadila Healthcare Ltd has informed BSE that Zydus Nycomed Healthcare Pvt Ltd, a 50:50 Joint Venture Company, set up by Zydus Cadila and Nycomed, will now be an API manufacturing hub with Nycomed planning to transfer its current API production from facilities at Linz (Austria) and Singen (Germany) to Zydus Nycomed in India over a period of four years. This would result in manufacture of 18 APIs. The new development comes in the wake of both Companies deciding to expand the scope of the existing JV Agreement and signing a letter of agreement to this effect.

In this regards the Company has issued the following Press Release:

“Zydus Nycomed, the 50:50 joint venture Company set up by Zydus Cadila and Nycomed, will now be an API manufacturing hub with Nycomed planning to transfer its current API production from facilities at Linz (Austria) and Singen (Germany) to Zydus Nycomed in India over a period of four years. This would result in manufacture of 18 APIs. The new development comes in the wake of both Companies deciding to expand the scope of the existing joint venture agreement and signing a letter of agreement to this effect.

Zydus Nycomed which has emerged as one of the most successful JV models is also a benchmark for high quality production at the most cost competitive prices. The joint venture Company was set up in 1999 to manufacture key starting materials for the production of Pantoprazole at the state-of-the-art plant at Navi Mumbai.

The agreement between the two Companies marks an important step in enhancing the competitiveness of Zydus Nycomed. By leveraging its expertise to address concerns of both costs and quality excellence, Zydus Nycomed will be a key sourcing base for Nycomed’s global API supplies.

Speaking on the newly expanded agreement, the Chairman and Managing Director of Zydus Cadila, Mr. Pankaj R Patel said, “The need to create a centre of excellence that sets the highest global standards in quality and service has been the very basis of this partnership. The new avenue that we have opened up strengthens this premise and will add a new dimension to the mutually beneficial partnership that exists between the two Companies.”

Cadila Healthcare Ltd has informed BSE that the Company has introduced an NDDS product “Nudoxa” for the treatment of various cancers, one of the critical drugs used in Chemotherapy, Nudoxa heralds a new approach in cancer therapy.

In this regards the Company has announced the following Press Release:

“Zydus Cadila has introduced an NDDS product ‘Nudoxa’ for the treatment of various cancers. One of the critical drugs used in chemotherapy, Nudoxa heralds a new approach in cancer therapy.

With chemotherapy being a common mode of treatment in cancers, there has been a long standing need for a drug that is stable and long lasting with reduced toxicity and side effects. Nudoxa addresses this need. A patented product in India and South Africa, patents for Nudoxa have also been filed in EU, US, Japan and several countries globally.

Doxorubiein, the first generation drug, was launched in 1960s and gave a new lease of life to cancer patients with its ability to combat aggressive and malignant tumours. This DNA-interacting drug, however, was discovered to cause life-threatening side effects in the form of cardiac abnormalities.

An advancement on this therapy resulted in liposomal doxorubiein in which the molecules of the drug are encapsulated in a fatty coating known as liposomes. The liposomes allow the doxorubiein lo be delivered specifically in greater amounts to the cancer cells, while having fewer side effects on the healthy tissues. A further advancement in this line of treatment was the Pegylated-liposomal doxorubiein, a unique form of liposomal doxorubicin in which the liposomes are coated with polyethylene glyeol, leading to a much longer half-life in the blood. However Pegylated-liposomal doxorubicin are likely to cause ‘Hand-Foot Syndrome,’ characterized by skin eruptions on the palms of the hand or soles of the feet, leading lo interruption in therapy.

A new variant liposomal doxorubiein Nudoxa with its unique drug delivery system is a breakthrough in cancer therapy as it offers the benefits of Pegylaled-liposomal doxorubiein without its major side effects like the Hand Foot syndrome. Marketed by Zydus Biogen, Nudoxa is manufactured by Zydus-BSV Pharma Pvt. Ltd., the joint venture company of Zydus Cadila and Bharat Serums and Vaccines Pvt. Ltd. Founded in 2005, Zydus-BSV Pharma focuses on targeted therapies in the area of Oncology.

Nudoxa is being used as a chemotherapy drug to treat various cancers, particularly, breast cancer - second most common type of cancer, ovarian cancer - the fifth-leading cause of cancer death in women, and AIDS-related Kaposi sarcoma which develops in people who are infected with the human immunodeficiency virus (HIV).